{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:47:39Z","timestamp":1786639659951,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000664","name":"NIHR Health Technology Assessment program","doi-asserted-by":"publisher","award":["NIHR155209"],"award-info":[{"award-number":["NIHR155209"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Flu Lab Limited Liability Company"},{"DOI":"10.13039\/100001263","name":"National Philanthropic Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche Products Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann\u2013La Roche AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Evidence-based effective treatments for hospitalized patients with influenza have yet to be identified. Traditional randomized controlled trials have struggled to provide definitive guidance due in part to small sample sizes and logistical challenges. Adaptive platform trials, such as REMAP-CAP (Randomised Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) and RECOVERY (Randomised Evaluation of COVID-19 Therapy), offer a transformative approach to evaluating influenza therapeutics. REMAP-CAP and RECOVERY utilize flexible, efficient designs that enable the simultaneous assessment of multiple interventions, adaptation to emerging data, and large-scale recruitment. Both platforms are currently evaluating antiviral and immunomodulatory therapies for severe influenza, building on their success in identifying effective treatments for COVID-19. Establishing global platform trials for influenza will facilitate the generation of high-quality evidence to guide seasonal influenza treatment and enhance pandemic preparedness. A coordinated international effort to sustain platform trials beyond pandemic periods is essential for improving clinical outcomes, optimizing resource utilization, and ensuring readiness for future pandemics.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf276","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:27:09Z","timestamp":1760668029000},"page":"S254-S261","source":"Crossref","is-referenced-by-count":14,"title":["Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-994X","authenticated-orcid":false,"given":"Alicia A C","family":"Waite","sequence":"first","affiliation":[{"name":"Centre for Inflammation Research, University of Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-2163","authenticated-orcid":false,"given":"Leon","family":"Peto","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-547X","authenticated-orcid":false,"given":"Anthony C","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics Pain Medicine and Intensive Care, Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-1586","authenticated-orcid":false,"given":"Peter","family":"Horby","sequence":"additional","affiliation":[{"name":"Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101622265849200_jiaf276-B1","first-page":"S177","article-title":"Use of influenza antivirals in pandemic response","volume":"232","author":"Zambon","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265849200_jiaf276-B2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025101622265849200_jiaf276-B3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(24)01307-2","article-title":"Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials","volume":"404","author":"Gao","year":"2024","journal-title":"Lancet"},{"key":"2025101622265849200_jiaf276-B4","first-page":"356","article-title":"Neuraminidase inhibitors and hospital length of stay: a meta-analysis of individual participant data to determine treatment effectiveness among patients hospitalized with nonfatal 2009 pandemic influenza A(H1N1) virus infection","volume":"221","author":"Venkatesan","year":"2020","journal-title":"J Infect Dis"},{"key":"2025101622265849200_jiaf276-B5","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J Infect Dis"},{"key":"2025101622265849200_jiaf276-B6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00134-011-2409-8","article-title":"Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic","volume":"38","author":"Annane","year":"2012","journal-title":"Intensive Care Med"},{"key":"2025101622265849200_jiaf276-B7","author":"European Centre for Disease Prevention and Control"},{"key":"2025101622265849200_jiaf276-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025101622265849200_jiaf276-B9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12916-020-01732-5","article-title":"Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009","volume":"18","author":"Rojek","year":"2020","journal-title":"BMC Med"},{"key":"2025101622265849200_jiaf276-B10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciz100","article-title":"Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness","volume":"69","author":"Gamino-Arroyo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025101622265849200_jiaf276-B11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"Beigel","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025101622265849200_jiaf276-B12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3851\/IMP2680","article-title":"Intravenous peramivir for treatment of influenza in hospitalized patients","volume":"19","author":"Ison","year":"2014","journal-title":"Antivir Ther"},{"key":"2025101622265849200_jiaf276-B13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","article-title":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III trial","volume":"151","author":"Hung","year":"2017","journal-title":"Chest"},{"key":"2025101622265849200_jiaf276-B14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1186\/s12889-020-09553-0","article-title":"Quantifying the direct secondary health care cost of seasonal influenza in England","volume":"20","author":"Moss","year":"2020","journal-title":"BMC Public Health"},{"key":"2025101622265849200_jiaf276-B15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1183\/09031936.00224814","article-title":"Antipyretic effect of dexamethasone in community-acquired pneumonia","volume":"46","author":"Vestjens","year":"2015","journal-title":"Eur Respir J"},{"key":"2025101622265849200_jiaf276-B16","author":"US Centers for Disease Control and Prevention"},{"key":"2025101622265849200_jiaf276-B17","author":"UK Health Security Agency"},{"key":"2025101622265849200_jiaf276-B18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13063-024-08156-z","article-title":"RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC)","volume":"25","author":"Knopman","year":"2024","journal-title":"Trials"},{"key":"2025101622265849200_jiaf276-B19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","article-title":"The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) study: rationale and design","volume":"17","author":"Angus","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2025101622265849200_jiaf276-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2022.23257","article-title":"Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume":"329","author":"Writing Committee for the REMAP-CAP Investigators","year":"2023","journal-title":"JAMA"},{"key":"2025101622265849200_jiaf276-B21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101622265849200_jiaf276-B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm Stat"},{"key":"2025101622265849200_jiaf276-B23","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222488","article-title":"Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial","author":"Derde","year":"2025","journal-title":"Thorax"},{"key":"2025101622265849200_jiaf276-B24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19","volume":"385","author":"ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101622265849200_jiaf276-B25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with COVID-19","volume":"385","author":"REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101622265849200_jiaf276-B26","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.7861\/fhj.2021-0083","article-title":"Making trials part of good clinical care: lessons from the RECOVERY trial","volume":"8","author":"Pessoa-Amorim","year":"2021","journal-title":"Future Healthc J"},{"key":"2025101622265849200_jiaf276-B27","doi-asserted-by":"crossref","first-page":"100901","DOI":"10.1016\/j.jbior.2022.100901","article-title":"Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial","volume":"86","author":"Peto","year":"2022","journal-title":"Adv Biol Regul"},{"key":"2025101622265849200_jiaf276-B28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Recovery Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101622265849200_jiaf276-B29","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Recovery Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"2025101622265849200_jiaf276-B30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1473-3099(23)00193-7","article-title":"International platform trials: as diseases cross borders, so should trials","volume":"23","author":"Saito","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_3\/S254\/64720090\/jiaf276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_3\/S254\/64720090\/jiaf276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:27:15Z","timestamp":1760668035000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/Supplement_3\/S254\/8287896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":30,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf276","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,10,15]]}}}